NVDA Price Target Hikes, NVO Gains on Wegovy FDA Approval, DAY Up Over 25%

Novo Nordisk (NVO) jumped higher after the FDA approved the company's Wegovy drug as a liver disease treatment. Dayforce (DAY) rallied more than 25% off reports that Thoma Bravo is looking to acquire the company. Nvidia (NVDA) has more bullish momentum heading into next week's earnings thanks to price target hikes from Morgan Stanley and Cantor Fitzgerald. Sam Vadas explains the biggest market movers starting the trading week.

Morning Trade Live

18 Aug 2025

SHARE

Schwab Network's Newsletters

Daily insights for every investor